Cytarabine/etidronic acid

Drug Profile

Cytarabine/etidronic acid

Alternative Names: Etidronate/cytosine arabinoside; Etidronic acid/cytarabine; MBC 11; MBC-11 -29

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MBC Pharma
  • Developer MBC Pharma; Osteros Biomedica
  • Class Antihypercalcaemics; Antineoplastics; Arabinonucleosides; Bisphosphonates; Calcium regulators; Drug conjugates; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Bone metastases

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Bone metastases in Russia (IV)
  • 02 Jun 2017 Efficacy and adverse events data from a phase I trial in Bone metastases presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Dec 2015 Osteros Biomedica completes a phase I trial in Bone metastases in Russia (IV) (NCT02673060)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top